What is Syndax Pharmaceuticals's investing cash flow?

Syndax Pharmaceuticals (SNDX) reported investing cash flow of $38.39M in Q1 2026.

How has Syndax Pharmaceuticals's investing cash flow changed year-over-year?

Syndax Pharmaceuticals's investing cash flow decreased by 59.2% year-over-year, from $94.14M to $38.39M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Syndax Pharmaceuticals SNDX Investing Cash Flow

Investing Cash Flow at other companies

BiogenBIIB

-$209.5M-343%

IncyteINCY

-$88.2M-8,140%

AbbVieABBV

-$574M+21.9%

ArriVent BioPharma, Inc.AVBP

$3.58M-90.3%

Viridian Therapeutics, Inc.VRDN

$77.26M-22.8%

Nuvation BioNUVB

-$43.64M-181%

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.74B+95.0%

Enterprise value$1.96B+84.0%

P/S8×-12.4×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's investing cash flow?: Syndax Pharmaceuticals (SNDX) reported investing cash flow of $38.39M in Q1 2026.
How has Syndax Pharmaceuticals's investing cash flow changed year-over-year?: Syndax Pharmaceuticals's investing cash flow decreased by 59.2% year-over-year, from $94.14M to $38.39M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.